bioM?rieux unscrewed the stock market
Influenza A (H1N1) has made the business of bioM?rieux in 2009. The group specialized solutions in vitro diagnostic announced Friday in its annual report a turnover of up to currencies and constant perimeter, from 7.7% to 1.223 billion euros for the whole financial year 2009 against 1.111 billion in 2008. In the fourth quarter, the improvement is significant. Over this period, sales jumped 7.5% to 328 million euros against 311 million in the fourth quarter of 2008.
However, bioM?rieux unscrews at the Paris Bourse. In fall of 5.1%, to 80.79 euros, as has one of largest declines in the Paris stock exchange in mid-day.Analysts consider that the upside potential of the title, given its current valuation is exhausted.
Sales made by influenza A (H1N1)
In Latin America, the group recorded the highest growth over the year 2009. The turnover in this region rose by 19.7% to 89 million instant payday loan . Sales have exploded in particular in Mexico. Logical reason: it is in this country has started the influenza A (H1N1). The application of clinical tests has been very high.
Influenza A (H1N1) has just boosted branch immunoassays, bioM?rieux. "The epidemic has had a favorable impact of approximately 18 million euros on sales of QuickVue influenza tests and systems NucliSENS easyMAG, or 150 basis points of organic growth," confirms the group.In Europe however, the virus activity had passed its peak, the impact on sales was lower in the fourth quarter.
The group's debt has been greatly reduced. He spent 51 million euros to 2 million a year. Side perspective, bioM?rieux table for 2010 organic growth of its sales in foreign currencies and constant perimeter, about 7%.
ALSO READ:
St?phane Bancel: "Our investments have increased during the crisis"